Tumor Cell Response to Bevacizumab Single Agent Therapy in Vitro

Cancer Cell International - United Kingdom
doi 10.1186/1475-2867-13-94
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Single Agent Therapy With Bevacizumab for the Treatment of Atypical Choroid Plexus Tumor

Kansas Journal of Medicine
2015English

Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

EMMPRIN Expression Is Required for Response to Bevacizumab Therapy in HNSCC Xenografts

Cancer Letters
Cancer ResearchOncology
2009English

Commentary on “Gemcitabine: Single‐Agent and Combination Therapy in Non‐Small Cell Lung Cancer”

Oncologist
Cancer ResearchMedicineOncology
1999English

Single-Cell Profiling Approaches to Probing Tumor Heterogeneity

International Journal of Cancer
Cancer ResearchOncology
2016English

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Single-Agent Plerixafor Mobilization to Collect Autologous Stem Cells for Use in Gene Therapy for Severe Sickle Cell Disease

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Real-Time Single-Cell Response to Stiffness

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

Efficacy of Bevacizumab Therapy in Recurrent Malignant Gliomas in Relation to the Prior Recurrence Pattern or Tumor Location

Journal of Clinical Neuroscience
MedicineSurgeryNeurologyPhysiology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy